Rheumatoid Arthritis News

    Skip to content
    • Home
    • Treatments
      • Tofacitinib (Xeljanz)
    • Experimental Treatments
      • Piclidenoson
      • Kevzara (Sarilumab)
      • Baricitinib (Olumiant)
    • About Us
    • Contact Us
    •
      June 12, 2017August 24, 2022

      Diplomat Pharmacy Begins Dispensing Kevzara to Treat Rheumatoid Arthritis

      Diplomat Pharmacy has begun filling prescriptions for Kevzara (sarilumab) for patients with moderate to severe rheumatoid arthritis (RA). The announcement comes after the U.S. Food and Drug ... Read more
    • June 7, 2017June 7, 2017

      Filgotinib Improves RA Patient Outcomes When Methotrexate Is Inadequate, Study Suggests

      Active rheumatoid arthritis (RA) patients whose response to methotrexate (MTX) therapy was insufficient showed improvement when MTX was combined with filgotinib, an investigational JAK–1 inhibitor, according ... Read more
    • June 5, 2017June 5, 2017

      EMA Accepts Humira and Remicade Biosimilars for Regulatory Review

      The European Medicines Agency (EMA) has accepted a marketing authorization application from generic pharmaceuticals developer Sandoz for the review of biosimilars for AbbVie’s Humira (adalimumab) and Janssen’s Remicade (infliximab), ... Read more
    • June 2, 2017June 2, 2017

      DMARDs Triple Therapy Provides Better Cost-Effective First Line Strategy for RA, Study Finds

      Results of a recent study showed that biological therapy regimens, such as Enbrel (etanercept), Humira (adalimumab), ‎Remicade (infliximab), ‎Simponi (golimumab), or ‎Cimzia (certolizumab), are less cost-effective ... Read more
    • May 23, 2017May 23, 2017

      Kevzara Approved by FDA for Treatment of RA in Adults Who Don’t Respond to DMARDs

      Kevzara (sarilumab) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with moderate to severely active rheumatoid arthritis ... Read more
    Phase 3 Clinical Trial Finds Drug, Baricitinib, of Benefit to Rheumatoid Arthritis Patients Who Failed at Other Treatments
    April 6, 2016April 6, 2016

    Phase 3 Clinical Trial Finds Drug, Baricitinib, of Benefit to Rheumatoid Arthritis Patients Who Failed at Other Treatments

    News
    Results from an international Phase 3 trial evaluating baricitinib as an rheumatoid arthritis (RA) treatment in patients who failed at other therapies reported a significant reduction in symptoms and increased physical function. Trial results were described in a ... Read more
    Pfizer’s MAA for Rheumatoid Arthritis Treatment Xeljanz to Be Reviewed by European Medicines Agency
    April 1, 2016April 1, 2016

    Pfizer’s MAA for Rheumatoid Arthritis Treatment Xeljanz to Be Reviewed by European Medicines Agency

    News
    The European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application for Pfizer’s Xeljanz (5 mg tablets twice daily) to treat adults with moderate to severely active rheumatoid arthritis in ... Read more
    Mesoblast’s Cell-Based Treatment of Rheumatoid Arthritis Granted US Patent
    March 30, 2016March 30, 2016

    Mesoblast’s Cell-Based Treatment of Rheumatoid Arthritis Granted US Patent

    News
    The U.S. Patent and Trademark Office has granted a key patent covering the use of Mesoblast Limited’s Mesenchymal Precursor Cells (MPCs) for the prevention or treatment of rheumatoid arthritis (RA) and ... Read more
    Rheumatoid Arthritis Drug, Vimovo Delayed-Release Tablets, Approved for US Patent
    March 28, 2016March 28, 2016

    Rheumatoid Arthritis Drug, Vimovo Delayed-Release Tablets, Approved for US Patent

    News
    Horizon Pharma has received a Notice of Allowance from the U.S. Patent and Trademark Office for its application covering Vimovo tablets, a fixed-dose combination of delayed-release enteric-coated naproxen (a non-steroidal anti-inflammatory drug, or NSAID), and immediate-release ... Read more
    Higher Risk of Developing Rheumatoid Arthritis Discovered in Women with PTSD, According to Study
    March 23, 2016March 23, 2016

    Higher Risk of Developing Rheumatoid Arthritis Discovered in Women with PTSD, According to Study

    News
    Women with post-traumatic stress disorder are at increased risk to developing rheumatoid arthritis, whether or not they smoke, according to a study recently published in the journal Arthritis Care & Research. Post-traumatic ... Read more
    Rheumatoid Arthritis Research Indicates Serotonin Could Be New Target for Therapies
    March 16, 2016March 16, 2016

    Rheumatoid Arthritis Research Indicates Serotonin Could Be New Target for Therapies

    News
    Researchers have shown for the first time that serotonin plays a fundamental role in the pathology of rheumatoid arthritis, through the regulation of essential regulatory immune cells and cells responsible ... Read more
    Phase 3 Trial Results Look Promising for Rheumatoid Arthritis Treatment Sarilumab
    March 14, 2016March 14, 2016

    Phase 3 Trial Results Look Promising for Rheumatoid Arthritis Treatment Sarilumab

    News
    Sanofi and Regeneron Pharmaceuticals recently announced their Phase 3 clinical trial met its primary endpoint: Sarilumab was superior to adalimumab (Humira) at Week 24 in improving signs and symptoms in 369 ... Read more
    Weight Gain, Loss in Rheumatoid Arthritis Patients Influenced by Disease-Modifying Drugs
    March 11, 2016March 11, 2016

    Weight Gain, Loss in Rheumatoid Arthritis Patients Influenced by Disease-Modifying Drugs

    News
    Of four disease-modifying antirheumatic drugs for patients with rheumatoid arthritis, leflunomide was most likely to cause weight loss and prednisone was most associated with weight gain, results of a study indicate. The ... Read more
    Rheumatoid Arthritis Successfully Treated with a Green Tea Compound in Animal Study
    March 7, 2016March 7, 2016

    Rheumatoid Arthritis Successfully Treated with a Green Tea Compound in Animal Study

    News
    Scientists have identified a compound in green tea that could be used to treat the joint pain, inflammation, and tissue damage caused by rheumatoid arthritis (RA). Their study, “Regulation of Transforming Growth Factor ... Read more
    Musculoskeletal Diseases Like Rheumatoid Arthritis Cost $213 Billion a Year in Treatment, Lost Wages
    March 4, 2016March 4, 2016

    Musculoskeletal Diseases Like Rheumatoid Arthritis Cost $213 Billion a Year in Treatment, Lost Wages

    News
    Musculoskeletal diseases, including rheumatoid arthritis, affect more than one out of every two people in the U.S. age 18 and over, and nearly three out of four age 65 and over ... Read more

    Posts navigation

    Older posts
    Newer posts

    Never miss another RA update.

    * indicates required
    Bionews, Inc.
    3 W Garden St
Suite 700
Pensacola, FL 32502
Email: [email protected]
Phone: +1-800-936-1363

    Recent Posts

    • Diplomat selling Kevzara

      Diplomat Pharmacy Begins Dispensing Kevzara to Treat Rheumatoid Arthritis

      June 12, 2017

    • Filgotinib Improves RA Patient Outcomes When Methotrexate Is Inadequate, Study Suggests

      June 7, 2017

    • Truxima, a biosimilar of rituximab

      EMA Accepts Humira and Remicade Biosimilars for Regulatory Review

      June 5, 2017

    • triple therapy

      DMARDs Triple Therapy Provides Better Cost-Effective First Line Strategy for RA, Study Finds

      June 2, 2017

    • About Us
    • Contact Us
    • Terms of Service
    • Privacy Policy

    Disclaimer:

    Rheumatoid Arthritis News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
    Copyright © 2013-2025 All rights reserved.